| Isolation and characterization of CD146+ multipotent mesenchymal stromal cells A Sorrentino, M Ferracin, G Castelli, M Biffoni, G Tomaselli, M Baiocchi, ... Experimental hematology 36 (8), 1035-1046, 2008 | 322 | 2008 |
| Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells U Testa, G Castelli, E Pelosi Cancers 10 (8), 248, 2018 | 279 | 2018 |
| Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells U Testa, E Pelosi, G Castelli Medical Sciences 6 (2), 31, 2018 | 266 | 2018 |
| miR-146 and miR-155: two key modulators of immune response and tumor development U Testa, E Pelosi, G Castelli, C Labbaye Non-coding RNA 3 (3), 22, 2017 | 197 | 2017 |
| Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor I Casella, T Feccia, C Chelucci, P Samoggia, G Castelli, R Guerriero, ... Blood, The Journal of the American Society of Hematology 101 (4), 1316-1323, 2003 | 189 | 2003 |
| MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis N Felli, F Pedini, P Romania, M Biffoni, O Morsilli, G Castelli, S Santoro, ... haematologica 94 (4), 479, 2009 | 181 | 2009 |
| Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells U Testa, E Petrucci, L Pasquini, G Castelli, E Pelosi Medicines 5 (1), 16, 2018 | 177 | 2018 |
| Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt YK Kim, SJ Kim, A Yatani, Y Huang, G Castelli, DE Vatner, J Liu, Q Zhang, ... Journal of Biological Chemistry 278 (48), 47622-47628, 2003 | 141 | 2003 |
| Liver cancer: molecular characterization, clonal evolution and cancer stem cells G Castelli, E Pelosi, U Testa Cancers 9 (9), 127, 2017 | 135 | 2017 |
| Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells E Pelosi, G Castelli, U Testa Biomedicines 5 (4), 65, 2017 | 105 | 2017 |
| Oxidative stress and hypoxia in normal and leukemic stem cells U Testa, C Labbaye, G Castelli, E Pelosi Experimental hematology 44 (7), 540-560, 2016 | 105 | 2016 |
| CD123 as a therapeutic target in the treatment of hematological malignancies U Testa, E Pelosi, G Castelli Cancers 11 (9), 1358, 2019 | 104 | 2019 |
| Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments U Testa, G Castelli, E Pelosi Medical Sciences 8 (1), 18, 2020 | 96 | 2020 |
| Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications U Testa, G Castelli, E Pelosi Medicines 6 (3), 82, 2019 | 86 | 2019 |
| Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation D Mastrangelo, E Pelosi, G Castelli, F Lo-Coco, U Testa Blood Cells, Molecules, and Diseases 69, 57-64, 2018 | 78 | 2018 |
| Esophageal cancer: genomic and molecular characterization, stem cell compartment and clonal evolution U Testa, G Castelli, E Pelosi Medicines 4 (3), 67, 2017 | 77 | 2017 |
| NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls β-globin and G-CSF receptor expression LM Starnes, A Sorrentino, E Pelosi, M Ballarino, O Morsilli, M Biffoni, ... Blood, The Journal of the American Society of Hematology 114 (9), 1753-1763, 2009 | 70 | 2009 |
| Human umbilical cord is a unique and safe source of various types of stem cells suitable for treatment of hematological diseases and for regenerative medicine E Pelosi, G Castelli, U Testa Blood Cells, Molecules, and Diseases 49 (1), 20-28, 2012 | 59 | 2012 |
| Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex M Gabbianelli, U Testa, O Morsilli, E Pelosi, E Saulle, E Petrucci, ... Haematologica 95 (8), 1253, 2010 | 57 | 2010 |
| Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy G Castelli, E Pelosi, U Testa OncoTargets and therapy, 131-155, 2017 | 54 | 2017 |
